drugset
drugset / Trial / NCT05191667

AN0025 and Chemoradiotherapy Combination in Esophageal Cancer

NCT05191667 ↗

Phase 1 Suspended 32 enrolled Adlai Nortye Biopharma Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, phase Ib study to evaluate the safety, tolerability, and preliminary efficacy of AN0025 in combination with chemoradiotherapy (CRT) in patients with locally advanced/locally recurrent esophageal cancer.

Timeline

Start
2022-01-18
Primary completion
2025-12
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject PALUPIPRANT Small molecule 250 mg Oral
Subject PALUPIPRANT Small molecule 500 mg Oral

Indications

esophageal cancer